AbbVie (ABBV) EBITDA Margin (2012 - 2026)

AbbVie (ABBV) has reported EBITDA Margin for 15 consecutive years, with 37.86% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 613.0% year-over-year to 37.86% in Q2 2026; TTM through Jun 2026 was 26.2%, a 740.0% increase from a year earlier, with the FY2025 full-year figure at 24.65%, up 843.0% from the prior year.
• EBITDA Margin was 37.86% for Q2 2026 at AbbVie, up from 26.6% in the prior quarter.
• Over five years, EBITDA Margin peaked at 37.86% in Q2 2026 and troughed at 9.87% in Q4 2024.
• A 5-year average of 24.97% and a median of 26.97% in 2025 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin slumped 3221 bps in 2024 and soared 3721 bps in 2025, its largest moves.
• Over 5 years, EBITDA Margin stood at 36.39% in 2022, then tumbled by 39 bps to 22.34% in 2023, then slumped by 144 bps to 9.87% in 2024, then jumped by 377 bps to 27.34% in 2025, then soared by 38 bps to 37.86% in 2026.
• The last three EBITDA Margin figures came in at 37.86% (Q2 2026), 26.6% (Q1 2026), and 27.34% (Q4 2025), per Business Quant data.